The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

By sjmartinez • December 2, 2024

Secord AA, Lewin SN, Murphy CG, Cecere SC, Barquín A, Gálvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Pérez MJR, Bonaventura A, Diver EJ, Ayuk SA, Wang Y, Corr BR, Salutari V. The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial. Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024.11.011. Epub ahead of print. PMID: 39617145.

Tags: antibody-drug conjugate, Folate receptor alpha, heavily pretreated (max 6), Infectious Diseases, Mirvetuximab soravtansine, Platinum-sensitive ovarian cancer, Publications

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton[...]

Cluster of Extensively Drug-Resistant Shigella sonnei Carrying blaCTX-M-15 in Los Angeles, California, 2023-2024

Caldera JR, Shaw B, Uslan DZ, Yang S. Cluster of Extensively Drug-Resistant Shigella sonnei Carrying blaCTX-M-15 in Los Angeles, California, 2023-2024. Am J Infect Control. 2024[...]

Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status

Lo Re V 3rd, Newcomb CW, Carbonari DM, Mezochow AK, Hennessy S, Rentsch CT, Park LS, Tate JP, Bräu N, Bhattacharya D, Lim JK, Mezzacappa[...]